Excerpt from the print edition of La Razón newspaper of Wednesday, October 4, 2023
Dr. Ramón Cacabelos is one of our most distinguished international scientists in the field of Neurosciences, Genomic Medicine and Pharmacogenetics of diseases of the Central Nervous System. He currently holds the positions of Professor of Genomic Medicine at the Faculty of Medicine of the Continental University of Peru, Director of the International Center of Neurosciences and Genomic Medicine in A Coruña, President of the EuroEspes Group, President of the World Association of Genomic Medicine (WAGEM) and President of the Spanish Society of Genomic Medicine.
In Neurogenomics, he stands out for the development and application of new genomic and epigenetic biomarkers and for being one of the first scientists in the world to promote personalized pharmacological treatment, through pharmacogenetic implantation, and for the development of Mylogy, an intelligent bioinformatics system that allows personalizing treatment based on the genomic profile of each person.
All this professional career has been awarded with numerous distinctions and now with the Career Achievement Award in Neurosciences and Genomic Medicine.
"I studied medicine out of a vocation of service. I specialized in Neurosciences and Genomics because the brain is the most enigmatic and complex organ of our body, key to individual dignity and because diseases of the nervous system are the most disabling in people's lives. I came to Genomics because I was convinced that knowledge of the human genome would end up revolutionizing the principles of medicine and would make it possible to establish a new approach to the integral approach to disease and the preservation of health", says Dr. Ramón Cacabelos.
The brain is the most complex organ, the key to individual dignity
Challenges of Neurosciences
Nervous system problems are the third most common health problem in the world, after cardiovascular diseases and cancer. The vast majority of these complex diseases have a familial basis, identifiable in more than 80% of cases by genomic screening. And another important characteristic is that these diseases begin to destroy our brains many years before they show symptoms. Consequently, "the great challenge for medicine in general, and clinical neurosciences in particular, is to be able to identify the risk of suffering from these diseases by means of genomic and epigenetic tracking in pre-symptomatic phases, in order to be able to implement prophylactic and preventive programs that neutralize or slow down the process of premature neuronal death and thus delay or avoid the manifestation of the disease," says Dr. Cacabelos. "The other great challenge is the development of antipathogenic drugs and bioproducts that attack the primary cause of the disease, in addition to alleviating the symptoms if the disease has already manifested; and the universal implementation of pharmacogenetics so that each patient receives the right type of drug based on his or her pharmacogenetic profile, which would avoid adverse effects, reduce the pharmaceutical cost of useless treatments and optimize the therapeutic performance of the drugs available," he says.